Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Antiangiogenic Therapy
100%
Histology
28%
Docetaxel
28%
Antiangiogenic
28%
Refractory Disease
28%
Chemotherapy
14%
Poor Prognosis
14%
Disease Progression
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Bevacizumab
14%
Adenocarcinoma
14%
Monotherapy
14%
Combination Treatment
14%
First-line Therapy
14%
Antiangiogenic Agents
14%
Unmet Medical Need
14%
Aggressive Disease
14%
Safety Self-efficacy
14%
Quality of Life Outcomes
14%
Nintedanib
14%
Life Safety
14%
Immunotherapy Agents
14%
Non-squamous Non-small Cell Lung Cancer
14%
Ramucirumab
14%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Antiangiogenic Therapy
100%
Disease
44%
Immunotherapy
22%
Antiangiogenic
22%
Docetaxel
22%
Disease Exacerbation
11%
Quality of Life
11%
Bevacizumab
11%
Adenocarcinoma
11%
Monotherapy
11%
Angiogenesis Inhibitor
11%
Nintedanib
11%
Ramucirumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Antiangiogenic Therapy
100%
Disease
44%
Immunotherapy
22%
Docetaxel
22%
Antiangiogenic
22%
Disease Exacerbation
11%
Chemotherapy
11%
Bevacizumab
11%
Adenocarcinoma
11%
Monotherapy
11%
Angiogenesis Inhibitor
11%
Ramucirumab
11%
Nintedanib
11%